Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Tyverb“
Suchtreffer
Begriffe & Kennungen
Tyverb · 4.5 · Lapatinib inhibits the transport protein Pgp in vitro at clinically relevant concentrations. Co-administration
Eintrag öffnenTyverb · 4.5 · Lapatinib inhibits the transport proteins BCRP and OATP1B1 in vitro. The clinical relevance of this effect has
Eintrag öffnenTyverb · 4.5 · Lapatinib is a substrate for the transport proteins Pgp and BCRP. Inhibitors (ketoconazole, itraconazole, quin
Eintrag öffnenTyverb · 4.5 · Lapatinib is predominantly metabolised by CYP3A (see section 5.2).
Eintrag öffnenTyverb · 4.5 · The bioavailability of lapatinib is increased up to about 4 times by food, depending on e.g. the fat content i
Eintrag öffnenTyverb · 4.5 · The solubility of lapatinib is pH-dependent. Concomitant treatment with substances that increase gastric pH sh
Eintrag öffnenTyverb · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenTyverb · 4.8 Undesirable effects · 1
Eintrag öffnenTyverb · 4.8 · 10 with capecitabine, as compared to 1.0 % with capecitabine alone. LVEF decreases were reported in 3.1 % of p
Eintrag öffnenTyverb · 4.8 · 9 Immune system disorders Rare Hypersensitivity reactions including anaphylaxis (see section 4.3) Metabolism a
Eintrag öffnenTyverb · 4.8 · A concentration dependent increase in QTcF (maximum mean ΔΔQTcF 8.75 ms; 90% CI 4.08, 13.42) was observed in a
Eintrag öffnenTyverb · 4.8 · Decreased left ventricular ejection fraction and QT interval prolongation
Eintrag öffnenTyverb · 4.8 · Description of selected adverse reactions
Eintrag öffnenTyverb · 4.8 · Diarrhoea
Eintrag öffnenTyverb · 4.8 · Diarrhoea occurred in approximately 65 % of patients who received lapatinib in combination with capecitabine,
Eintrag öffnenTyverb · 4.8 · Hepatotoxicity
Eintrag öffnenTyverb · 4.8 · Left ventricular ejection fraction (LVEF) decreases have been reported in approximately 1% of patients receivi
Eintrag öffnenTyverb · 4.8 · No additional adverse reactions were reported to be associated with lapatinib in combination with trastuzumab.
Eintrag öffnenTyverb · 4.8 · Rash occurred in approximately 28 % of patients who received lapatinib in combination with capecitabine, in 45
Eintrag öffnenTyverb · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnen